These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34587799)

  • 1. Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?
    Iles KA; Thornton M; Park J; Roberson M; Spanheimer PM; Ollila DW; Gallagher K
    Am Surg; 2022 Mar; 88(3):471-479. PubMed ID: 34587799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Miligy IM; Awasthi R; Mir Y; Khurana A; Sharma V; Chandaran U; Rakha E; Maurice Y; Kearns D; Oweis R; Asar A; Ironside A; Shaaban AM
    Histopathology; 2024 Sep; 85(3):405-417. PubMed ID: 38845397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers.
    Miligy IM; Badr N; Stevens A; Spooner D; Awasthi R; Mir Y; Khurana A; Sharma V; Chandaran U; Rakha EA; Maurice Y; Kearns D; Oweis R; Asar A; Ironside A; Shaaban AM
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients-A NCDB analysis (2010-2016).
    Xu P; Luo W; Hu J; Ma X; Hao Q; Hui W; Zhou Z; Lin S; Wang M; Wu H; Dai Z; Kang H
    Cancer Med; 2024 Jun; 13(11):e7244. PubMed ID: 38859692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice.
    Badr NM; Spooner D; Steven J; Stevens A; Shaaban AM
    Histopathology; 2021 Jul; 79(1):47-56. PubMed ID: 33423290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
    Chen K; Quan J; Yang J; Chen Z
    Clin Transl Oncol; 2020 Apr; 22(4):576-584. PubMed ID: 31209793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
    Rimawi MF; Mayer IA; Forero A; Nanda R; Goetz MP; Rodriguez AA; Pavlick AC; Wang T; Hilsenbeck SG; Gutierrez C; Schiff R; Osborne CK; Chang JC
    J Clin Oncol; 2013 May; 31(14):1726-31. PubMed ID: 23569315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delays in operative management of early-stage, estrogen receptor-positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study.
    Di Lena É; Hopkins B; Wong SM; Meterissian S
    Surgery; 2022 Mar; 171(3):666-672. PubMed ID: 34862071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
    Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
    Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database.
    LeVasseur N; Willemsma KA; Li H; Gondara L; Yip WC; Illmann C; Chia SK; Simmons C
    Clin Breast Cancer; 2019 Dec; 19(6):e683-e689. PubMed ID: 31279611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
    Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE; Costantino JP; Land SR; Wolmark N
    J Clin Oncol; 2012 Apr; 30(12):1268-73. PubMed ID: 22393101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status.
    Vugts G; Van den Heuvel F; Maaskant-Braat AJG; Voogd AC; Van Warmerdam LJC; Nieuwenhuijzen GAP; Van der Sangen MJC
    Breast J; 2018 Nov; 24(6):894-901. PubMed ID: 30033607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.